Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

1 treatments under study, led by Experimental Group

Related Conditions

Often studied with 9 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

Trial Status

Unknown2
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT03269474Unknown

Computational Drug Repurposing for All EBS Cases

NCT04154839Unknown

Epidemiological Survey and Genetic Analysis of AD Patients in Hong Kong

NCT00001292CompletedPrimary

Study of Scaling Disorders and Other Inherited Skin Diseases

Showing all 3 trials

Research Network

Common Treatments

  • Experimental Group1

Active Sponsors

  • Joyce Teng1
  • The University of Hong Kong1
  • National Cancer Institute (NCI)1
  • The Hong Kong Polytechnic University1

Top Investigators

Related Conditions

  • Epidermolysis Bullosa1
  • Keratosis Follicularis1
  • Epidermolysis Bullosa Junctional1
  • Epidermolysis Bullosa Simplex1
  • Lamellar Ichthyosis1

Activity Timeline